Panacea Biotec Ltd. (PANACEABIO)

Overview

Panacea Biotec Limited stands as a prominent biotechnology entity in India, specializing in the innovation-driven domains of research and development, production, and dissemination of pharmaceutical formulations along with vaccines. The firm's operations are bifurcated into two primary segments: Vaccines and Formulations, catering to a diverse range of therapeutic needs and public health demands. With its founding year marked as 1984, Panacea Biotec has established its headquarters in New Delhi, India. The company has not only made its mark domestically but also on a global scale, exporting its pharmaceutical products to over 36 countries across continents including North America, Europe, Africa, and Asia. Furthermore, Panacea Biotec has been at the forefront in combating global health crises by entering into strategic collaborations for Covid-19 vaccine production and development of vaccine candidates against various coronavirus strains and potential future threats.

Products and Services

• Prescription Products:

  Panacea Biotec's range of prescription products encompasses a vast therapeutic spectrum, aimed at addressing critical areas of healthcare such as pain management, diabetes and cardiovascular diseases, oncology, renal disease, osteoporosis, and gastro-intestinal care. Each product is the result of rigorous research and is designed to meet the highest standards of quality and efficacy.

• Vaccines:

  The company's commitment to public health is further evidenced by its extensive vaccine portfolio, which includes:

  • Pneumococcal Vaccine: Targeting one of the leading causes of pneumonia across varied age groups, this vaccine plays a crucial role in preventing pneumococcal disease.
  • Dengue Tetravalent Vaccine: A sophisticated formulation designed to combat all four serotypes of the dengue virus, providing broad protection against this life-threatening disease.
  • Typhoid Conjugate Vaccine: Offering a long-term defense against typhoid fever, this vaccine is pivotal in efforts to reduce the global burden of this bacterial infection.
  • Universal Flu Vaccine: Innovatively crafted to provide immunity against multiple strains of influenza, this vaccine represents a significant advancement in flu prevention.
• Global Exports:

  Beyond its domestic achievements, Panacea Biotec has effectively penetrated international markets, exporting its high-quality pharmaceutical products and vaccines to countries such as the United States, Germany, Russia, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Philippines, Sri Lanka, among others. This global footprint underscores the company's commitment to enhancing healthcare standards worldwide.

• Strategic Collaborations:

  In the wake of the COVID-19 pandemic, Panacea Biotec has strategically partnered with the Russian Direct Investment Fund for the production of the Sputnik-V vaccine. In addition, it has joined forces with the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute focusing on the development of vaccine candidates. These initiatives are aimed at strengthening global defenses against SARS-Cov-2 variants and other Beta coronaviruses, highlighting Panacea Biotec's pivotal role in global health security.